Zhitong Finance App News, Kexing Pharmaceuticals (688136.SH) issued an announcement. Recently, the company received the “Notice of Acceptance” approved and issued by the State Drug Administration regarding the marketing license application for the drug polyethylene glycolated human granulocyte-stimulating factor injection (“GB-K02” for short). The company's GB-K02 is suitable for patients with non-myeloid malignant tumors to reduce the incidence of infections characterized by febrile neutropenia when receiving myelosuppressive anticancer drugs that are likely to cause clinically significant febrile neutropenia.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.